PFCS
DSGN icon

Pale Fire Capital SE’s Design Therapeutics DSGN Stock Holding History

Pale Fire Capital SE’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,500
Closed -$27.8K – 61
2023
Q4 		$27.8K Buy
+10,500
New +$24.1K ﹤0.01% 73

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pale Fire Capital SE's DSGN Position: Q1 2024 in Review

Pale Fire Capital SE sold out of Design Therapeutics (DSGN) in Q1 2024, closing a stake of 10,500 shares — an estimated $27.8K sold.

Pale Fire Capital SE first reported a position in DSGN in Q4 2023 and held it in 1 quarter. The position peaked at $27.8K in Q4 2023. 93 funds tracked by Wall St. Rank hold DSGN as of Q1 2024.

  • Pale Fire Capital SE reported no remaining Design Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Pale Fire Capital SE sold 10,500 Design Therapeutics shares in Q1 2024, an estimated $27.8K.
  • Pale Fire Capital SE first reported a position in Design Therapeutics in Q4 2023 and held it in 1 quarter.
  • Pale Fire Capital SE's Design Therapeutics position peaked at $27.8K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2024.

Based on Pale Fire Capital SE's 13F filing for Q1 2024, filed 14 May 2024.